Michael Barbella, Managing Editor04.15.23
New product news topped readers' preferences on ODT's website this past week.
Taking the lead was FDA's marketing authorization for Moximed's MISHA knee system, and implantable shock absorber (ISA) for the knee. MISHA is indicated to treat those with knee osteoarthritis who were unable to find relief from non-surgical or surgical treatment, continue to have pain that interferes with daily activities, and are ineligible for (or unwilling to undergo) joint replacement because of age or absence of advanced OA. In its recent Calypso pivotal study, Moximed was able to demonstrate superiority of MISHA over high tibial osteotomy (HTO), a well-established surgery. The company used the established benefits of load reduction on knee joints to design the system, which is implanted in an outpatient-compatible procedure.
Enovis drove significant traffic with the launch of its Enofix with Constrictor technology, the latest addition to its suite of foot and ankle products. Enofix is a repair system that, according to the company, has demonstrated superior fixation under cyclic loading.
Enofix with Constrictor offers foot and ankle surgeons a syndesmotic repair system with a knotless, adjustable, and low-profile button. The suture is a custom Dunamis Medical fiber composed of UHMWPE (ultra-high molecular weight polyethylene).
Reach Neuro, meanwhile, amassed pageviews for winning FDA Breakthrough Device designation for its Avantis platform. Avantis delivers small electrical impulses to the spinal cord to help restore shoulder, arm, and hand movement to patients with impairment due to chronic stroke. The breakthrough status aims to address the unmet need for the nearly 7.5 million Americans living with post-stroke disability, according to the company.
Besides the new product news, cybervisitors also showed interest in Novadip Biosciences' positive clinical trial data for NVD-003 and an online exclusive about the global biomaterial market's evolution.
Taking the lead was FDA's marketing authorization for Moximed's MISHA knee system, and implantable shock absorber (ISA) for the knee. MISHA is indicated to treat those with knee osteoarthritis who were unable to find relief from non-surgical or surgical treatment, continue to have pain that interferes with daily activities, and are ineligible for (or unwilling to undergo) joint replacement because of age or absence of advanced OA. In its recent Calypso pivotal study, Moximed was able to demonstrate superiority of MISHA over high tibial osteotomy (HTO), a well-established surgery. The company used the established benefits of load reduction on knee joints to design the system, which is implanted in an outpatient-compatible procedure.
Enovis drove significant traffic with the launch of its Enofix with Constrictor technology, the latest addition to its suite of foot and ankle products. Enofix is a repair system that, according to the company, has demonstrated superior fixation under cyclic loading.
Enofix with Constrictor offers foot and ankle surgeons a syndesmotic repair system with a knotless, adjustable, and low-profile button. The suture is a custom Dunamis Medical fiber composed of UHMWPE (ultra-high molecular weight polyethylene).
Reach Neuro, meanwhile, amassed pageviews for winning FDA Breakthrough Device designation for its Avantis platform. Avantis delivers small electrical impulses to the spinal cord to help restore shoulder, arm, and hand movement to patients with impairment due to chronic stroke. The breakthrough status aims to address the unmet need for the nearly 7.5 million Americans living with post-stroke disability, according to the company.
Besides the new product news, cybervisitors also showed interest in Novadip Biosciences' positive clinical trial data for NVD-003 and an online exclusive about the global biomaterial market's evolution.
